Efficiency comparison of an isoeugenol-derivated compound, eugenosedin-A, with glibenclamide and pioglitazone in protecting cardiovascular dysfunction of diabetic SHR

J Asian Nat Prod Res. 2023 May;25(5):471-483. doi: 10.1080/10286020.2022.2096597. Epub 2022 Jul 19.

Abstract

This study was to investigate three agents possible protective effect against DM-induced cardiovascular dysfunction in spontaneously hypertensive rats (SHR). Control group was fed normal diet, DM group was injected with STZ/NA and fed high fat diet (HFD), and treatment groups were given STZ/NA, fed HFD, and then oral gavaged with eugenosedin-A (Eu-A), glibenclamide (Gli), or pioglitazone (Pio) 5 mg/kg/per day for 4-week, respectively. Eu-A, Gli, and Pio clearly ameliorated the changes of body weight, cardiac weight, and the biochemical parameters, cardiovascular disorders and inflammation. Like Gli and Pio, Eu-A may be effectively to control DM and the cardiovascular dysfunction.

Keywords: Eugenosedin-A; cardiovascular dysfunction; diabetes mellitus; glibenclamide; pioglitazone.

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental* / drug therapy
  • Glyburide* / adverse effects
  • Hypoglycemic Agents / pharmacology
  • Pioglitazone / adverse effects
  • Rats
  • Rats, Inbred SHR
  • Rats, Sprague-Dawley

Substances

  • Pioglitazone
  • eugenosedin-A
  • Glyburide
  • Hypoglycemic Agents
  • isoeugenol